Category VIEW ALL
Next-Generation Regenerative Therapy for Wound Healing
Technology No. BRA08-01
First-in-Class Vaccine Platform to Halt Prion Transmission Across Species
Technology No. WIS02-20
Novel Immune Based Therapeutic Strategies to Target Tumors with Alterations in LKB1 Pathway
Technology No. PAP02-04
Non-Genetic Induction of Tumor Neoantigens via Translational Errors
Technology No. BAN03-02
Targeting the Stress-Response Pathway to Promote Anti-tumor Responses
Technology No. PAP02-05
Tumor-Targeting Nanoparticles for Precision Chemotherapy in Cancer
Technology No. TRA02-06
Biomimetic Nanofibers Electrospun with Calreticulin as Wound Healing Agents
Technology No. GOL01-10
Inhibitory Peptides That Selectively Antagonize Neuropilin 1 (NRP1) for Precise Pain Treatment
Technology No. BUN01-02
Peptidomimetic Modulator of CaV2.2 N-type Calcium Channel for Treatment of Chronic Pain
Technology No. KHA03-01
Platform for Locally Assembling Antibody Drug Conjugates (ADCs) With Enhanced Specificity
Technology No. NEE02-08
Enhancing Neuronal Resistance to Neurodegeneration
Technology No. MAZ02-03
Mutant-Selective HER2 Antibodies for Treatment of Major Cancer Types
Technology No. KOI01-08
A Biomarker for Cerebral Amyloid Angiopathy (CAA) and Amyloid Related Imaging Abnormality Risk
Technology No. WIS02-27
Cysteine Depletion as a Treatment for Obesity and Associated Metabolic Disorders
Technology No. LIT01-56
Sindbis Virus-Based Vectors for the Oncolytic Immunotherapy of Solid Tumors
Technology No. MER02-24
Monoclonal Antibodies for Efficient Removal of Uremic Toxins in Chronic Kidney Disease Patients
Technology No. KON02-10
Repurposing Farnesyl Transferase Inhibitors for the Treatment of Cerebral Malaria
Technology No. ROD01-17
Apoptosis Inhibitor 5 (API5)-based Therapeutic for the Treatment of Inflammatory Bowel Diseases
Technology No. CAD01-05
S-allylcysteine for Use in the Prevention and Treatment of Plasma Cell Dyscrasias
Technology No. ORL01-32
Topical Inhibition of HIF-1a as a Novel Therapeutic Strategy for Inflammatory Skin Diseases
Technology No. NAI02-03
Clinical Prognostic Models for Stage II Melanoma Using Tumor miRNA Signatures
Technology No. POL01-05
Multivalent Assembled Proteins (MAPs): Therapeutics for Cancer and Infectious Diseases
Technology No. MON02-11
Drug Targets for Overcoming Resistance to KRAS G12C Inhibitors (G12Cis) in Cancer
Technology No. NEE02-05
Novel Probiotic Compositions for Improving Metabolism and Immunity
Technology No. BLA02-12
Therapeutic Hyaluronic Acid and Peptide Composition for Regenerative Repair of Cartilage Injury
Technology No. COW02-02
Injectable Therapeutic Hydrogel for the Treatment of Post-Traumatic Osteoarthritis
Technology No. LIU02-02, MON02-04
Hydrophobically Interspaced, Charged Peptides for the Treatment and Prevention of Dementia
Technology No. WIS02-26
Anti-CD97 Antibody-Drug Conjugates for the Treatment of AML and GBM
Technology No. KOI01-16
Salt-Inducible Kinase Activators to Treat Bone and Mineral Diseases
Technology No. PAR07-01
Small Molecule Inhibitors of SPNS2 for the Treatment of Chronic Inflammatory Diseases
Technology No. SCH14-01
Methods of Sensitizing Estrogen Receptor-Positive Breast Cancer to Endocrine Therapy
Technology No. SCH03-09
Apolipoprotein B Peptide Mimics for Atherosclerosis Treatment
Technology No. GOL05-04
Targeting Endocytosis in Nociceptors as a Non-Opioid Treatment Strategy for Chronic Pain
Technology No. BUN01-01
Treatment of Melanoma Brain Metastasis by Inhibition of Amyloid Precursor Protein Cleavage
Technology No. HER02-07
Method of Treating Lung Cancer in Patients with LKB1 Genetically-Inactivated Tumors
Technology No. WON02-07
Vectored ACE2 Receptor Decoy for Prevention and Treatment of Pan-Coronavirus Infections
Technology No. LAN02-06
Nanobodies Targeting SARS-CoV-2 NSP9 for COVID Treatment
Technology No. PER03-04
iScore: A Novel Method for Improved Risk Stratification of AML Patients
Technology No. AIF01-12
Novel Targets for Cancer Therapy
Technology No. WON02-04
Treatment for Alzheimer’s Disease by Inhibiting Formation of Platelet Micro-Clots
Technology No. WIS02-24
Osteoarthritis (OA) Biomarker Suitable as a Point-of-Care Diagnostic
Technology No. WIS01-03
Therapeutic Targeting of KMT2D Mutant Lung Cancer Via RTK-RAS Signaling Inhibition
Technology No. WON02-05
Targeting the SARS-CoV-2 Viral-Immune Interaction for COVID-19 Therapy
Technology No. WAN05-01
Viral Vector Expression of Gabrb1b for the Treatment of Perceptual Deficits
Technology No. SAN06-01
Novel miRNA and Protein Therapeutic Targets to Reduce Atherosclerosis
Technology No. HUS02-04
Targeting a Novel Metabolic Network for Pancreatic Ductal Adenocarcinoma (PDAC) Treatment
Technology No. KIM06-01
Paper-Based, Multiplexed Lamp Diagnostic for Pathogen Detection
Technology No. QAS01-09
Engineered Progranulin: A Promising Therapeutic Approach for Autoimmune Diseases
Technology No. LIU02-03
Multivalent Steroid Conjugates for Treatment of Castration-Resistant Prostate Cancer (CRPC)
Technology No. KIR01-10
Netrin-1 and UNC5B as Novel Targets in Metabolic Liver Diseases: NAFLD & NASH
Technology No. MOO02-06
FGF23 Ligand Trap: New Biologic for Treating Kidney Diseases
Technology No. MOH01-02
Chimeric FGF21: Treatment of NAFLD, NASH and Hepatic Steatosis
Technology No. MOH01-03
Angiotensin-Converting Enzyme 2 (ACE2) Immunoadhesin Microbody
Technology No. LAN02-03
Nano Zeolite-Y: A Novel and Cost-Effective Antibacterial Composition
Technology No. ANI01-01
Targeting RNA Viruses Using Inhibitors of METTL3
Technology No. MOH02-08
Anti-CD99 Antibodies Cytotoxic to Leukemia
Technology No. KOI01-05
TET2 Modulators for the Treatment of Cancer and Inflammatory Diseases
Technology No. AIF01-09
Novel Biomarkers for Detection and Treatment of Immune Deficiencies During Pregnancy
Technology No. HAN04-01
Non-Antibiotic Treatment of Staphylococcal Infections
Technology No. NOV01-14
Succinate Receptor 1 (SUCNR1) Antagonists to Treat Neuroinflammation
Technology No. LI06-03
NSP14/10 Complex Inhibitors for the Treatment of SARS-CoV-2 and Pan-Coronavirus Infections
Technology No. PAG01-15
Novel MicroRNA-30c Analogs to Reduce Secretion of Apolipoprotein B in Human Hepatoma Cells
Technology No. HUS02-03
A Novel Blood Marker for Prognostication and Treatment of Non-Small Cell Lung Cancer
Technology No. PAS02-13
Transgenic Mouse Model Expressing C217G Uromodulin
Technology No. WU01-01
